Gelonghui, December 28 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that the company's Chinese herbal medicines are mainly used in the company's own production and operation, and their procurement and production have long-term plans and arrangements, and the relevant Chinese herbal medicine varieties will set a safe inventory according to the company's actual production needs. When the prices of some varieties of Chinese herbal medicines are relatively low, the company will make a certain amount of strategic reserves. Up to now, the company's inventory has shown no signs of depreciation, and the short-term impact of Chinese herbal medicine price waves on the company's operations is minimal.
The company's investment funds mainly focus on medical services, medical informatization, cutting-edge technology in the medical industry with high added value and high threshold, and pharmaceutical fields such as domestic commercial rights and innovative biopharmaceuticals. Currently, there are no major changes. As a shareholder holding 5% or more of the company's shares, Harbin Yuxi Venture Capital Co., Ltd. must strictly comply with relevant laws and regulations to fulfill its obligation to disclose information in accordance with relevant laws and regulations. Currently, the company has not received a notice of its holdings reduction plan, and there are no related transactions with the actual controller. Due to seasonal factors and other factors, the number of patients attending the company's hospitals has recently increased; the Wudang Hospital affiliated to Guizhou Medical University, which is affiliated with the company, has a plastic surgery department, and is currently carrying out programs such as eye and nose surgery, microplastic injections, and photorejuvenation. The above medical treatment changes and medical service programs contributed less to the company's revenue.